Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV(-) and HPV(+) Head and Neck Cancers To TNF α, TRAIL, and Radiation Therapy.

CONCLUSIONS: IAP1/XIAP antagonist ASTX660 sensitizes HPV(+) HNSCC to TNFα via a mechanism involving restoration of TP53. The present findings serve to motivate further studies of dual cIAP/XIAP antagonists and future clinical trials combining these antagonists with radiotherapy to treat both HPV(+) and (-) HNSCC. PMID: 31266830 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31266830?dopt=Abstract

Source: Clinical Cancer Research - July 1, 2019 Category: Cancer & Oncology Authors: Xiao R, An Y, Ye W, Derakhshan A, Cheng H, Yang X, Allen C, Chen Z, Schmitt NC, Van Waes C Tags: Clin Cancer Res Source Type: research